No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DTIL Precision BioSciences
- 10.1000
- -0.7900-7.25%
Close Jun 18 16:00 ET
- 10.4600
- +0.3600+3.56%
Post 16:57 ET
69.95MMarket Cap-1344P/E (TTM)
10.8950High10.1000Low35.22KVolume10.7600Open10.8900Pre Close369.12KTurnover0.74%Turnover RatioLossP/E (Static)6.93MShares21.900052wk High1.88P/B48.11MFloat Cap8.250052wk Low--Dividend TTM4.76MShs Float710.1060Historical High--Div YieldTTM7.30%Amplitude8.2500Historical Low10.4800Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, today announced that the company w
Express News | Precision BioSciences Inc: Ind and/or Cta on-Track for Submission in 2024
Express News | Precision BioSciences Inc: Pbgene-Hbv Was Well Tolerated Across Multiple Administrations With No off-Target Editing Observed
Express News | Precision BioSciences Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate at the European Association for the Study of the Liver Congress
Precision BioSciences to Participate in Upcoming June Investor Conferences
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
Buy Rating on Precision BioSciences: Leading the Way in Gene Editing for Chronic Hepatitis B
Comments
$Precision BioSciences(DTIL.US$ Benzinga· just
Precision BioSciences Announces Common Stock Purchase By Members Of Management, Including CEO, For $300,000 In Private Placement
Precision BioSciences Announces Common Stock Purchase By Members Of Management, Including CEO, For $300,000 In Private Placement
2
$Precision BioSciences(DTIL.US$
NEWS
PRECISION BIOSCIENCES ANNOUNCES COMMON STOCK PURCHASE BY MEMBERS OF MANAGEMENT FOR $300,000 IN A PRIVATE PLACEMENT
NEWS
PRECISION BIOSCIENCES ANNOUNCES COMMON STOCK PURCHASE BY MEMBERS OF MANAGEMENT FOR $300,000 IN A PRIVATE PLACEMENT
1
$Precision BioSciences(DTIL.US$ Reuters· 3 mins ago
Precision BioSciences Announces Receipt of FDA Fast Track Designation for Ecur-506, Iecure’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (Otc) Deficiency
Precision BioSciences Announces Receipt of FDA Fast Track Designation for Ecur-506, Iecure’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (Otc) Deficiency
1
$Precision BioSciences(DTIL.US$ The best news is useless to this piece of crap.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg